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Abstract
Background: Due to the growing number of elderly with advanced chronic conditions, healthcare services will
come under increasing pressure. Teleconsultation is an innovative approach to deliver quality of care for palliative
patients at home. Quantitative studies assessing the effect of teleconsultation on clinical outcomes are scarce. The
aim of this present study is to investigate the effectiveness of teleconsultation in complex palliative homecare.
Methods/Design: During a 2-year recruitment period, GPs are invited to participate in this cluster randomized
controlled trial. When a GP refers an eligible patient for the study, the GP is randomized to the intervention group
or the control group. Patients in the intervention group have a weekly teleconsultation with a nurse practitioner
and/or a physician of the palliative consultation team. The nurse practitioner, in cooperation with the palliative care
specialist of the palliative consultation team, advises the GP on treatment policy of the patient. The primary
outcome of patient symptom burden is assessed at baseline and weekly using the Edmonton Symptom
Assessment Scale (ESAS) and at baseline and every four weeks using the Hospital Anxiety and Depression Scale
(HADS). Secondary outcomes are self-perceived burden from informal care (EDIZ), patient experienced continuity of
medical care (NCQ), patient and caregiver satisfaction with the teleconsultation (PSQ), the experienced problems
and needs in palliative care (PNPC-sv) and the number of hospital admissions.
Discussion: This is one of the first randomized controlled trials in palliative telecare. Our data will verify whether
telemedicine positively affects palliative homecare.
Trial registration: The Netherlands National Trial Register NTR2817
Background
Palliative care has become an important public health
issue since the past decade [1]. The ageing of the popu-
lation and the rising life expectancy are contributing to
this development. Also, the pattern of diseases people
suffer and die from has changed from acute illnesses
towards chronic illnesses [1-3]. In addition to advances
in medical knowledge and technology that increase
treatment possibilities at the end of life, these epidemio-
logical transitions have led to a growing need of pallia-
tive care in the last phase of life [4].
The primary goal of palliative care is to ensure the
best possible quality of life of patients and their families
facing a life threatening illness [1,5]. Most people in
their end-stage of life, regardless of their initial disease,
want to be cared for and to die at home [6,7]. There-
fore, place of death is considered an indicator of quality
of end-of-life care [8]. However, research in Belgium
and in the Netherlands has shown that 30-40% of pallia-
tive patients are transferred from home to a hospital or
health care institution in the last week of life [9,10].
This trend is also seen internationally [11]. Transitions
in the location of care are often extremely stressful for
patient and caregivers [11] and can pose a challenge for
the continuity of care [11,12].
Place of death has also become a topic of wider inter-
est for public health policy, due to the focus in health
care on cutting costs in acute care settings [13]. Many
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to reduce the number of acute care hospital beds as a
means to restrict hospital expenditure [5]. With this
shift in location of care for the seriously ill from hospital
to home, the reliance on family caregivers to support
patients with terminal illness at home is growing [13].
These family caregivers are of vital importance for those
wanting to die at home. Without them, remaining at
home in the last phase of life would be impossible for
many patients [14,15]. However, caregiving for termin-
ally ill patients can be burdensome for informal care-
givers, possibly leading to burn-out [16,17].
Due to a growing number of palliative patients and
the desire for less institutionalized care, community-
based palliative care will become a big challenge [18].
The development of innovative approaches to deliver
good quality of care at home is therefore necessary. One
such approach is the use of telemedicine. Telemedicine
is the use of telecommunications and information tech-
nologies to share and maintain patient health informa-
tion and to provide clinical care and health education to
patients and professionals when distance separates the
patients [19]. Teledermatologic consultation has been
one of the first applications of telemedicine. Literature
shows that this form of teleconsultation reduces the
number of traditional face-to-face consultations with a
dermatologist [20-23]. In addition, a telemedicine
approach has also been proven cost-effective in diabetes
care and pediatrics [24,25]. In the field of palliative
homecare however, few quantitative studies have been
carried out [26-30]. These studies often are of moderate
methodological quality. Common shortcomings are
small sample sizes, comparability of intervention and
control groups and the handling of drop-outs [26,31].
Teleconsultation is a specialized form of telemedicine
that uses technology to pro v i d er e a l - t i m ev i s u a la n d
audio patient assessment [32]. Teleconsultation is an
instrument to bring across expertise from the hospital
into primary healthcare and can therefore be very useful
in complex homecare for palliative patients and their
families. This study aims to evaluate the effectiveness of
teleconsultation in palliative homecare. The primary
goal is to evaluate the effectiveness of teleconsultation
on the symptom burden of palliative patients at home.
Secondary objectives are 1) to investigate whether tele-
consultation influences the number of hospital admis-
sions by acting more pro-active on escalating problems
of patients, 2) to consider if the burden of the family
caregiver changes by giving them a better opportunity
to address their needs and problems, 3) to study the
patient experienced continuity of medical care in the
last phase of life, 4) to assess patient and caregiver satis-
faction with the teleconsultation contact and 5) to inves-
tigate patient’s problems and needs for palliative care.
The objective of this report is to present the protocol
of the study used for data collection in 2011 and 2012.
Methods/Design
Study design
The study consists of a two-armed cluster randomized
controlled trial. To prevent possible bias at the level of
GPs, a clustering will take place on the level of the GP.
The symptom burden of the patient and the secondary
outcomes in the two study arms will be compared.
Parallel to this cluster randomized controlled trial, a
qualitative study will be undertaken. In this qualitative
study, semistructured interviews and observations will
be used to consider the socio-ethical aspects of telecon-
sultations in palliative homecare. The findings from the
quantitative and the qualitative study will be integrated
in future articles.
Randomization
Participating GPs will be randomly assigned to the inter-
vention group or to the control group. Due to clustering
of GPs, all subsequently referred patients will be in the
same study group. A block design with different length
of blocks (4 and 6) will be used to give an equal balance
between groups. An independent researcher will gener-
ate and store the randomization code.
Study population
On the moment of inclusion, the patient’sG Pa c t sa s
the coordinator of medical care, and patients reside at
their homes. Besides the place of residence, the inclu-
sion criteria are:
- Dutch-speaking patients, aged 18 years or older,
with a progressive oncological disease,
-as c o r eo f≤ 60 on the Karnofsky Performance
Scale (assessed by the GP),
- a life expectancy of ≤ 3 months.
Patients unable to give informed consent and patients
with an active psychotic disorder or a serious cognitive
disorder are not eligible for inclusion.
Intervention
After completing the baseline measurement, a telemedi-
cine computer will be installed at the patient’sh o m e .
Soon after the installation, the nurse practitioner of the
consultation team contacts the patient to make an
appointment for the first teleconsultation. During this
first digital screen-to-screen contact between the patient
and the nurse practitioner, the nurse checks for pro-
blems in palliative care following a predefined consulta-
tion protocol (e.g. physical problems, social problems,
coordination of care). After the first teleconsultation,
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care specialist of the palliative consultation team, advises
the GP on the treatment policy for the patient. During
this trajectory, the GP continues to be the coordinator
of medical care. The teleconsultations will return every
week, but more frequent contact is possible when the
patient and the team desire this. There are no installa-
tion or internet costs for the patient and also the use of
the telemedicine computer is for free.
The telemedicine application is a computer with a
touch screen, a microphone/speaker and a camera.
Large and easy to understand pictograms make the pro-
gram user-friendly. To contact a nurse or a physician
for a videoconference, the patient just has to touch the
image of that person. In addition to the weekly telecon-
sultations, the patient also has the opportunity to video-
phone the 24/7 support service of the homecare
organization. Furthermore, an information database, an
internet-browser and some entertainment options are
available on the telemedicine application. The telemedi-
cine application will not be used in emergency situations
due to safety restrictions.
Collaborating organizations
This research protocol is granted by The Netherlands
Organisation for Scientific Research (NWO). The pro-
ject is coordinated by the Department of Anesthesiology,
Pain and Palliative Medicine of the Radboud University
Nijmegen Medical Centre. This department works in
close collaboration with the Department of Primary and
Community Care. ZZG Zorggroep, a regional homecare
organization, provides the patients with a 24/7 support
service. Finally, an ICT-installation company (Focus-
Cura) installs the telemedicine application at the
patient’s home and also provides technical support.
Recruitment, consent and data collection
For the purpose of this study, all GPs practicing in the
Nijmegen region are invited with a letter, in which the
a i ma n dp r o c e d u r eo ft h es t u d ya r ec l a r i f i e d .F u r t h e r -
more, the advantages and disadvantages of participating
are mentioned and contact information for advice from
an independent physician is given. The researcher con-
tacts the GPs several days after receipt of the letter.
When more information is needed, the researcher visits
the GP to inform him/her more extensively about the
trial. When a GP refuses to participate, the researcher
will document the arguments for non-respondent analy-
sis. Inclusion starts at April 1 2011 and runs to October
1 2012.
When the patient and the family caregiver decide to
join the study, they sign the informed consent form dur-
ing a one-hour home visit by the researcher. After
informed consent, the patient and the family caregiver
will first complete the baseline measurement. The base-
line measurement consists of several demographic ques-
tions and four short questionnaires for the patient. The
four questionnaires (ESAS, PNPC-sv, HADS and NCQ)
will be completed at home every four weeks during the
study participation. The ESAS will be completed every
week, as symptom burden is our primary outcome. The
family caregiver completes a questionnaire on self-per-
ceived pressure from informal care (EDIZ) at baseline
and every two weeks. At time points where there is no
home visit, the ESAS and EDIZ will be returned in a
stamped envelope. The family caregiver receives a
mobile phone text message as a reminder to fill in and
post the questionnaires. The flowchart of the inclusion
is described in Figure 1.
Outcome measures
Primary outcome
The symptom burden experienced by the patient, using
the Edmonton Symptom Assessment System (ESAS)
and the Hospital Anxiety and Depression Scale (HADS).
Secondary outcomes
1. The number of hospital admissions, which will be
obtained from the patient’s file.
2. The experienced problems and needs for palliative
care (PNPC-sv; Problems and Needs in Palliative Care).
3. Patient and caregiver satisfaction with the telecon-
sultation (PSQ; Patient Satisfaction Questionnaire).
4. The experienced continuity of medical care in the
last phase of life (Nijmegen Continuity Questionnaire;
NCQ).
5. The experienced burden of the family caregiver
(EDIZ; self-perceived pressure from informal care).
Other study outcomes
1. We will ask for some demographic information, such
as age, marital status, number of children and living
situation.
2. After the period of study inclusion (from the GPs
patient record):
￿ Number of contacts by telephone with the GP
practice
￿ Number of home visits by the GP
￿ Number of contacts with the GPs out of hours
service
￿ Number of patients with complex interventions
(such as palliative sedation)
￿ Number of and indications for hospital admissions
￿ Date and place of death
Measurement instruments
T h ev u l n e r a b l ec o n d i t i o no ft h ep a t i e n t sw a sa ni m p o r -
tant point of departure in the selection of the
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of the questionnaire, difficulty, the number of question-
naires and the time points of measurement. When it is
impossible for the patient to complete the question-
naires independently, the informal caregiver is allowed
to assist the patient. Table 1 gives an overview of the
questionnaires used in the study.
Primary outcome
The ESAS is an easy to complete questionnaire devel-
oped for use in daily symptom assessment of palliative
care patients. The patient rates the presence and severity
of the following nine symptoms common in cancer
patients: pain, activity, nausea, depression, anxiety,
drowsiness, appetite, sense of well-being and shortness
of breath. An optional tenth symptom can be added by
the patient [33]. The items are rated on 0-10 visual
numerical scales (with 10 being the worst imaginable
intensity of a symptom). The ESAS is widely used and
proven to be reliable [34,35].
The HADS is a 14-item self-report screening scale
that was originally developed to indicate the possible
presence of anxiety and depressive states in the setting
 
 
GP informs researcher about 
an eligible patient 
Researcher sends information 
letter to patient and family 
caregiver 
Informed consent and baseline 
measurement in the presence 
of the researcher 
Control Group 
Care as usual  Randomization 
ICT installation company 
installs telemedicine 
computer at the patient’s 
home within 3-5 days 
Weekly teleconsultations with 
the nurse practitioner of the 
palliative consultation team  
Intervention Group 
Weekly teleconsultation 
Figure 1 Flowchart of the inclusion.
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tains two 7-item subscales on anxiety and depression.
Each item scores on a 4-point Likert scale. The ques-
tionnaire assesses symptoms over the preceding week
[36]. Psychometric properties of the HADS were
assessed in six different groups of Dutch subjects (N =
6165). Homogeneity and test-retest reliability of the
total scale and the subscales were considered adequate.
The dimensional structure and reliability of the HADS
is considered to be stable across medical settings and
age groups [37].
Secondary outcomes
The PNPC is a self-reporting questionnaire for patients
covering all dimensions of palliative care to investigate
their problems and (unmet) palliative care needs.
Experienced problems and needs for care are addressed
separately, because patients could have had adequate
assistance despite enduring symptom suffering. The ori-
ginal questionnaire with its 90 items has shown validity
and reliability, but is not always practical for palliative
patients. Therefore, a short version of 33 items has been
developed and validated. This PNPC- short version was
tested on 94 patients with metastatic cancer and has
demonstrated construct validity. The dimension reliabil-
ity was satisfactory, although two domains were less
coherent [38].
The PSQ is a 5-item visual-analogue screening tool to
measure patients’ satisfaction, as well as doctor’ss a t i s -
faction, following the consultation [39]. The question-
naire is developed and tested in the home situation in
the Netherlands. Physician satisfaction turned out to be
substantially lower than patient satisfaction, both at item
level and at overall satisfaction level [39]. This finding is
consistent with other patient satisfaction studies [40,41].
T h eP S Qi sas h o r ta n de a s yt of i l li nq u e s t i o n n a i r e
compared to many other patient satisfaction question-
naires and is therefore a very suitable instrument for the
vulnerable patients participating in this study. The ques-
tionnaire will be completed by the patient, a member of
the palliative consultation team and the GP following
the first two teleconsultations.
The NCQ is developed and validated by the Radboud
University Nijmegen Medical Centre (Department of
Primary and Community Care). The questionnaire mea-
sures the patients’ experienced continuity of care across
primary and secondary care settings and consists of 3
subscales: ‘Personal or relational continuity: care provi-
der knows me’ (5 items), ‘Personal continuity: care pro-
vider shows commitment’ (3 items) and ‘Team/cross-
boundary continuity’ (4 items). Items are scored on a 5-
point Likert scale, with an additional option to choose
‘?’ (’do not know’). The NCQ was tested on 268 patients
with a chronic disease and proved to be a reliable and
valid instrument with good discriminant abilities [Uijen
AA, Schellevis FG, Mokkink HGA, van Weel C, van den
Bosch WJHM, Schers HJ: Measuring continuity from
the patient perspective: psychometric properties of the
Nijmegen Continuity Questionnaire (NCQ), submitted].
In this study, only the domains on the experienced qual-
ity of the relation between GP and specialist and the
confidence in the GP and in the specialist are being
used. Publications on the development of the question-
naire and the examination of the reliability and validity
have been submitted to a journal and are available on
request.
The EDIZ is a 5-point Likert scale screening question-
naire with 9 subjects to measure the self-perceived bur-
den from informal care. This burden is expressed in
thoughts (e.g. ‘the situation of my.... is constantly on my
mind’) as well as in his/her interaction with the social
environment (e.g. ‘it’s not easy to combine the responsi-
bility for my ... with the responsibility for my work/
family’). The EDIZ is a validated instrument [42].
Sample size calculation
The null hypothesis of this cluster randomized trial is
that there are no significant differences in symptom dis-
tress between palliative patients at home with and with-
out a telemedicine-computer for videoconference.
Symptom distress will be measured by the Edmonton
Symptom Assessment Scale (ESAS). The ESAS is a 0 to
10 numeric scale (0 = best, 10 = worst) to rate severity
of 10 symptoms. The sum of all 10 scales makes the
Total Distress score (max.100). Based on a study of
Table 1 Questionnaires used in the study
Patient questionnaires
Administered at baseline
￿ Basic demographic information (7 questions)
Administered at baseline and every week
￿ ESAS (Edmonton Symptom Assessment System)
- 10 items on symptom assessment
Administered at baseline and every four weeks
￿ PNPC-sv (Problems and Needs in Palliative Care - short version)
- 33 questions on experienced problems and needs for care
￿ HADS (Hospital Anxiety and Depression Scale)
- 14 items on anxiety (7 items) and depression (7 items)
￿ NCQ (Nijmegen Continuity Questionnaire)
- 28 items within 3 subscales on continuity of care
Family caregiver questionnaire
Administered at baseline and every two weeks
￿ EDIZ (one dimensional assessment of care burden)
- 9 items on the experienced burden from informal care
Patient, GP and a member of the palliative consultation team
Administered after the first two teleconsultations
￿ PSQ (Patient Satisfaction Questionnaire)
- 5 questions on satisfaction with the teleconsultation
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of 8 as the minimum clinically important difference for
the power calculation. Without a cluster-effect and
without repeated measures, we would need 80 patients
per condition, assuming an a of .05 and a power of 80%
(calculated with nQuery advisor 4.0). However, there is
a cluster-effect and there are repeated measures that we
corrected for.
To correct for clustering, we multiplied the above-
mentioned sample size with the design factor (1+(n-1)
ICC), where n is the number of patients and ICC the
intra cluster correlation. Assuming 3 enrolled patients
per GP and an ICC of 0,1 (based on Knox & Chondros
[44]), the design factor for clustering is 1,2.
To correct for repeated measures and baseline mea-
surement, we also multiplied the sample size with the
design factor ((1+(k-1)r)/k- r0
2). In this formula, k is
the number of repeated measures, r is the (mean) corre-
lation between pairs of post-tests and r0 is the (mean)
correlation between a post-test and the baseline mea-
surement. Here, k = 13, and we state r = 0,45 [34] and
r0 = 0,35. The design factor for repeated measures is
therefore 0,37.
That makes the total required sample size 80 × 1,2 ×
0,37 = 36 patients per condition. Taking into account
an early drop-out of patients, we aim to include 50
patients per condition. This calculation is based on Foll-
well et al. [43], who considered a drop-out of 30%
within an inclusion period of 1 month. Because the
inclusion period in our study is longer (estimated life-
expectancy of approximately 3 months at inclusion), we
chose a higher drop-out percentage (39%).
Put briefly, a sample size of 100 patients (a = .05,
power = 80%) is required to detect differences in change
of symptom distress between the intervention group and
the control group.
Statistical analysis
The data will be stored and analyzed in the Radboud
University Nijmegen Medical Centre using the Statistical
Package for the Social Sciences (SPSS version 16.0, SPSS
inc., Chicago, Illinois, USA). Data cleaning will be per-
formed via SPSS syntax operations. All statistical tests
will be done two-tailed with 95% confidence intervals.
Descriptive statistics
Normally distributed quantitative data will be analyzed
by mean and standard deviation. Data that are not nor-
mally distributed will be reported by median and inter-
quartile range. Qualitative data will be reported by
frequency distributions and percentages.
Multivariate analysis
Our primary goal is to detect differences in the ESAS
and HADS-scores between groups of patients with and
without the telemedicine application. Because the study
design involves a pretest, repeated measures and cluster-
ing, data will be analyzed with Linear Mixed Models.
This method of analysis will also be used to describe
our secondary outcome measures (EDIZ, NCQ, PNPC-
sv, PSQ, number of hospital admission).
Ethical considerations
Actively participating in the teleconsultations and com-
pleting the questionnaires can be burdensome for this
vulnerable group of patients, particularly towards the
end of the study period when the condition of the
patient worsens. Therefore, the researcher, the GP and
the palliative consultation team always take into account
the condition of the patient when a research activity will
be undertaken. The disadvantages of participating, as
well as the advantages, are clearly mentioned in the
information letter to patient and informal caregiver.
The protocol of the present study was approved by the
Central Committee on Research Involving Human Sub-
jects (CCMO) Arnhem/Nijmegen.
Discussion
This study investigates the effectiveness of teleconsulta-
tion in complex palliative homecare. It compares clinical
outcomes in the intervention group with a control
group. The intervention consists of a weekly teleconsul-
tation with the palliative consultation team. Bringing
specialist expertise to the home via video-telephone
technology is an innovative way of improving complex
homecare for palliative patients. A strength of our study
is the robust design. We plan to conduct a cluster ran-
domized controlled trial, which will be one of the first
in palliative homecare, at least in the field of telemedi-
cine. Furthermore, symptom burden is our primary out-
come measure. Studies with clinical outcome measures
are scarce in research on palliative homecare. Therefore,
future data on this primary outcome measure, when
positive, will be very helpful in the adoption and imple-
mentation of telemedicine services in palliative care.
However, there are also several challenges in this
study. A first challenge will be to enroll a sufficiently
l a r g es a m p l et om a k es u r et h a td i f f e r e n c e sb e t w e e nt h e
intervention group and the control group can be
detected. If recruitment problems occur, the palliative
consultation team and the regional home care organiza-
tion will additionally be involved. Finally, this research
project stimulates collaboration between primary care
and hospital care in order to optimize the continuity of
care. Besides this process innovation, we also focus on
technical/product innovation. In a world where technol-
ogy is changing rapidly, it is a big challenge to carry out
innovative research.
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